KEYWORDS: Bioglan, the Swedish subsidiary of the Spanish pharmaceutical company, and STADA Arzneimittel AG have signed an agreement to expand the production…
treatment
-
-
Ropeginterferon
FDA Approves Ropeginterferon Alfa-2b-njft (Besremi) Treatment for Rare Blood Disease Polycythemia Vera (PV).
by adminby adminSUMMARY: PharmaEssentia Corporation a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in…
-
AstraZenecaDapagliflozin
NICE issues Draft Recommendation for AstraZeneca`s Forxiga (Dapagliflozin) to Treat Adults with Chronic Kidney Disease
by adminby adminAbstract: The National Institute for Health and Care Excellence (NICE) has issued an Appraisal Consultation Document (ACD) for AstraZeneca’s Forxiga (Dapagliflozin) within…
-
Pharma Science & Research
ICEBERG Study Demonstrates Improved Outcomes Of Esketamine Nasal Spray For Treatment-Resistant Depression
by adminby adminSUMMARY: Janssen’s ICEBERG study has demonstrated that Esketamine nasal spray (NS) has shown improved outcomes in an indirect treatment comparison with other…
-
Active Pharmaceutical Ingredients (API)ATG-101Pharma Science & Research
Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma.
by adminby adminKEYPOINTS; Antengene Corporation Limited announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for…
-
Agrochemicals
AstraZeneca has agreed to transfer its global rights for respiratory medicines Eklira (Aclidinium bromide) and Duaklir (Aclidinium bromide/formoterol) to Covis Pharma Group.
by adminby adminKEYPOINTS AstraZeneca has agreed to transfer its global rights to Eklira (Aclidinium bromide), known as Tudorza in the US, and Duaklir (Aclidinium…
-
Asciminib
FDA approves Novartis Scemblix® (Asciminib) for Certain Patients with Philadelphia Chromosome (Ph)–positive Chronic Myeloid Leukemia.
by adminby adminKeypoints: The FDA granted accelerated approval to Asciminib for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia for 2 indications.…
-
Pitolisant
Bioprojet’s Ozawade (Pitolisant) gets Approval for the Treatment of Excessive Daytime Sleepiness (EDS) associated with Obstructive Sleep Apnoea (OSA) in Adults.
by adminby adminSUMMARY: EMA-approved medicine for excessive daytime sleepiness med Ozawade (Pitolisant) Pitolisant was developed after decades of research by Bioprojet co-founders Dr. Jeanne-Marie Lecomte and Prof. Jean-Charles…
-
CompaniesNovartis
Novartis’s BLA has been accepted by US FDA & EMA for Kymriah (Tisagenlecleucel) to treat patients with relapsed or refractory follicular lymphoma.
by adminby adminNovartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T cell therapy Kymriah (Tisagenlecleucel) as third-line therapy…
-
CompaniesPfizer
BioNTech Deal With Senegal, Rwanda to Make mRNA Vaccine in Mid 2022
by adminby adminSummary- BioNTech in bid to build manufacturing expertise in Africa Project seeks to avoid repeat of COVID-19 vaccine inequality Backed by EU…